Fobi AI Selected By GPJ, World's Leading Experience Marketing Agency, To Provide Wallet Pass Solution For Global Enterprise Client Launch Of INEOS Grenadier 4X4. Deal Generates Immediate and Recurring Revenue
Fobi selected by the world’s leading event and experience marketing agency GPJ to utilize their Wallet pass solution as part of a complete event management solution for their global client INEOS’ new vehicle launch, which will deliver revenue this quarter and recurring revenue moving forward.
VANCOUVER, British Columbia, July 20, 2021 (GLOBE NEWSWIRE) -- FOBI AI Inc. (TSXV: FOBI) (OTCQB: FOBIF:) (the "Company" or "Fobi"), a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement is pleased to announce it has been selected by GPJ, the world’s leading event & experience marketing agency, to utilize its Wallet pass solution to develop a custom event management system including ticketing and booking functionality, for INEOS, one of GPJ’s global enterprise clients.
GPJ GLOBAL ENTERPRISE CLIENTS INCLUDE 40 IN FORTUNE 500. INEOS GENERATES $61 BILLION IN ANNUAL REVENUE.
GPJ employs over 1,300 people through a global office network that delivers integrated experiential programs via digital, mobile and physical brand activations. Their clients include AT&T, American Express, BMW, Chrysler, Facebook, Google, Mercedes-Benz, Pepsi, P&G and many more global power brands.
INEOS is a GPJ client employing over 26,000 people across 29 countries and generating $61 billion in annual revenue. INEOS is making an impact across a range of elite sports including Formula One, cycling, sailing, football, and running and becoming increasingly known to consumers with the launch of the INEOS Grenadier 4x4, which is powered by BMW..
FOBI EVENT MANAGEMENT SYSTEM (EMS) FOR INEOS WENT LIVE JULY 18TH TO SUPPORT GLOBAL PROMOTION OF NEW 4X4. GPJ EXPECT FURTHER FOBI CUSTOM SOLUTIONS FOR CLIENTS
The INEOS Grenadier 4x4 is being promoted via a roadshow event across multiple countries and locations. INEOS is transporting prototypes of the vehicle to several locations within each region and required a solution to allow users to book test drives of the new 4x4.
Fobi’s new Event Management Solution (EMS) is a sophisticated, end-to-end resource for booking and ticketing developed using the Fobi Wallet pass, SimplyBook’s calendaring system and a client branded booking webpage which was custom built by Fobi. Fobi EMS allows INEOS to engage with their guests using a solution that manages resources, digitizes ticketing, and automates bookings and event-based notifications.
GPJ Creative Technologist, Zara Kerwood stated “Fobi has been instrumental in making this experience successful for INEOS with their Wallet pass solution that can be used to create a new and more efficient communication and ticketing tool that leverages the mobile wallet. We are excited to see the results and to work with FOBI on custom solutions for our other clients.”
Fobi CEO Rob Anson stated “We are experiencing great success with revenue generating deals working directly with agencies like GPJ. We are excited to be selected to build a custom solution for a top client such as INEOS that helps pave the way for better user experiences and assists enterprise clients in building end-to-end customer experience platforms. We are very confident in this project and are looking forward to working with GPJ on similar projects in the future.”
The expected success of this project and continued relationship with GPJ will open the door for FOBI to work with some of GPJ’s extensive client list including Fortune 500 companies such as Nissan, Jeep, Adobe, Samsung, Salesforce and others.
PROJECT MARKS FOBI’S CONTINUED TRANSITION TO PAID DEALS, WITH A CONTRIBUTION TO REVENUE THIS QUARTER & MOVING FORWARD
This deal will deliver solid revenue for Fobi this quarter, as well as monthly recurring revenue thanks to the fees for the Wallet pass licenses. This model will be easily repeatable with other GPJ client event related projects. As a result of our latest integrated booking product, we anticipate significant additional revenue generating contracts to be announced in the coming months.
GPJ RELATIONSHIP PART OF FOBI’S STRATEGY TO TARGET LARGE GLOBAL AGENCIES THAT PRESENT FOBI SOLUTIONS TO THEIR ENTERPRISE CLIENTS
Fobi’s unique EMS also enables a new marketing and engagement channel for businesses to increase lead generation and generate revenue. The solution enables businesses to utilize the Wallet pass to push notifications and engagements that enable a smoother customer experience and better customer acquisition.
ABOUT GEORGE P JOHNSON EXPERIENCE MARKETING (GPJ)
George P Johnson Experience Marketing (GPJ) is the world’s leading Event and Experience Marketing Agency. GPJ operates primarily as a marketing and advertising firm, providing digital, multimedia, and physical marketing interactions, as well as offering brand management services and consulting, however GPJ specializes in more traditional physical event management. GPJ has a wide variety of clients in various industries: automotive, technology, software, food & beverage, entertainment, including over 40 Fortune 500 Companies. GPJ are part of Project Worldwide – an independent, global network of wholly owned creative agencies. It spans advertising, branding, design, e-commerce, live events, PR, talent booking, shopper marketing and social media – and we’re proud to work together in service of creativity.
INEOS is a global petrochemicals manufacturer operating 194 sites across 29 countries, generates $61 billion annually and employs over 26,000 people. They work across several markets ranging from agriculture, chemicals, electronics, medical & pharma, textiles, and several more. In addition, INEOS is making an impact across a range of elite sports including Formula One, cycling, sailing, football, and running and becoming increasingly known to consumers, with the launch of the Grenadier and INEOS Hygienics.
FOBI is a cutting-edge data intelligence company that helps our clients turn real-time data into actionable insights and personalized customer engagement to generate increased profits. FOBI's unique IoT device has the ability to integrate seamlessly into existing infrastructure to enable data connectivity across online and on-premise platforms creating highly scalable solutions for our global clients. FOBI partners with some of the largest companies in the world to deliver best-in-class solutions and operates globally in the retail, telecom, sports & entertainment, casino gaming, and hospitality & tourism industries.
For more information, please contact:
|FOBI AI Inc.||FOBI Website: www.fobi.ai|
|Rob Anson, CEO||Facebook: @ FOBIinc|
|T: +1 877-754-5336 Ext. 4||Twitter: @ FOBI_inc|
|E: firstname.lastname@example.org||LinkedIn: @ FOBIinc|
This news release contains certain statements which constitute forward-looking statements or information, including statements relating to the use of proceeds from the Offering. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond the Company's control, including the impact of general economic and capital markets conditions, stock market volatility and the ability to access sufficient capital from internal and external sources. Although the Company believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future plans, operations, results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, the Company does not undertake any obligation to publicly update or to revise any of the included forward looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of the Company should be considered highly speculative. There can be no assurance that the Company will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Cavotec wins key motorised cable reel order for advanced container cranes in Japan26.7.2021 09:00:00 CEST | Press release
Cavotec has won a key order for its innovative motorised cable reel systems for integration onto advanced rail-mounted gantry cranes at the Port of Tokyo – a project that highlights Cavotec’s position as a trusted supplier of mission-critical systems at ports and terminals. “Given the complexity of these high-end cranes and their demanding operational environment, this is an excellent reference for us as we continue to grow in Japan and the wider region,” says Robin Shang, Cavotec Regional Sales Director Ports & Maritime. Cavotec will supply motorised cable reel systems for eight automated rail-mounted gantry (ARMG) cranes at the Wan Hai Tokyo Oi5 terminal, a major global container handling hub. The cable reels will ensure the cranes meet demanding performance requirements due to surging container volumes. Working closely with Chin Pan engineering group, Cavotec is scheduled to complete the delivery of the systems in early 2023. Previously, Chin Pan has fitted two ARMGs cranes successf
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme26.7.2021 08:44:35 CEST | Press release
Company Announcement No. 38/2021 Copenhagen, 26 July 2021 Transactions in connection with share buy-back programme On 10 March 2021, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 600 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2022. The following transactions have been executed from 19 July to 23 July 2021: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement1,781,412222,947,59319 July 202120,000125.242,504,78020 July 202115,510125.551,947,26
Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity26.7.2021 08:00:00 CEST | Press release
PRESS RELEASE July 26, 2021 Tesomet is the first and only investigational treatment for hypothalamic obesity to receive orphan drug designation Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO). Tesomet is the first and only investigational treatment for HO to receive orphan drug designation. Saniona is preparing to initiate two Phase 2b studiesof Tesomet in the second half of this year, one in HO and the other in Prader-Willi syndrome (PWS), for which Tesomet has already received orphan drug status. “There are currently no FDA-approved medicines for hypothalamic obesity. Despite the devastating weight gain and hunger this rare disease can cause, there has been relatively little drug development specifically for HO. Saniona is proud to be pioneering a regulatory path forward for people li
SERSTECH AB: Half-year report 1 January – 30 June 202126.7.2021 08:00:00 CEST | Press release
Serstech Group Second quarter 2021 Net sales: KSEK 2 765 (308)Profit for the period: KSEK -5 299 (-6 820)Earnings per share: SEK -0.06 (-0.10)Earnings per average number of shares: SEK -0.07 (-0.10) Serstech Group Period 1 January - 30 June 2021 Net sales: KSEK 14 224 (6 321)Profit for the period: KSEK -2 270 (-10 025)Earnings per share: SEK -0.03 (-0.14)Earnings per average number of shares: SEK-0.03 (-0.14) The second quarter brought a slight increase in orders received compared to the previous quarter, but we clearly see remaining effects of the pandemic in most parts of the world. We have not lost any tenders during the quarter, which is encouraging and again suggests that there is an unmet demand in the market. We do expect an increase in sales over the next six months, as the buyers become more active and the important demo sessions can be arranged safely again. Buyers in our industry will not buy an instrument they have not tested themselves and therefore they postpone procureme
Reminder of an Investor Conference Webinar26.7.2021 08:00:00 CEST | Press release
We would like to remind that KN invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the July 29th of 2021 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and acting Chief Financial Officer Indrė Kisielienė who will introduce the performance and unaudited financial results of KN for the six months of 2021. How to join the webinar? To join the webinar, please register via following link: https://register.gotowebinar.com/register/6420133473151346701You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can't be downloaded, a web browser which enables attending the webinar, opens automatically. The webinar will be recorded and available online for everyone at the company’s we
Van Lanschot Kempen’s partnership with Mercier Vanderlinden finalised26.7.2021 08:00:00 CEST | Press release
’s-Hertogenbosch/Amsterdam, the Netherlands, 26July2021 Van Lanschot Kempen and Mercier Vanderlinden today announced that they have completed the transaction that sees Van Lanschot Kempen acquire a 70% stake in Mercier Vanderlinden. The regulators have issued declarations of no objection, and Van Lanschot Kempen and Mercier Vanderlinden have thus joined forces in the Belgian wealth management market. Van Lanschot Kempen will increase step-by-step its 70% stake in Mercier Vanderlinden to 100%. Mercier Vanderlinden and Van Lanschot Kempen in Belgium will continue to operate independently and collaborate in a number of areas. The partners are a good fit in terms of client portfolios and networks, product offering and geographical coverage. Between them, they had €9.3 billion in client assets at 30 June 2021. In the past few years, both Van Lanschot Kempen in Belgium and Mercier Vanderlinden have achieved robust client asset growth, and they will continue their role as market challengers o
Saniona får särläkemedelsklassning av FDA för Tesomet mot hypotalamisk fetma26.7.2021 08:00:00 CEST | Pressemelding
PRESSMEDDELANDE 26 juli 2021 Tesomet är det första och enda prövningsläkemedlet för behandling av hypotalamisk fetma som erhållit särläkemedelsklassning Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att det amerikanska läkemedelsverket FDA har beviljat särläkemedelsklassning av Tesomet för behandling av hypotalamisk fetma (HO). Tesomet är det första och enda prövningsläkemedlet för behandling av HO som erhållit särläkemedelsklassning. Saniona förbereder starten av två Fas 2b-studier med Tesomet under andra halvåret i år, en på HO och den andra på Prader Willis syndrom där särläkemedelsstatus redan erhållits. ”Det finns i nuläget inga FDA-godkända läkemedel för hypotalamisk fetma. Trots den förödande viktuppgång och hunger som den sällsynta sjukdomen kan orsaka har relativt lite läkemedelsutveckling specifikt inom HO-området. Saniona är stolta över att bryta ny mark för människor som lever med HO och vi är myck